Athyrium Capital Managementfirm invested in uMotifcompany on May 25, 2022.
Websiteitem pageThe website reads: “uMotif Announces $25.5m Investment from Fund Managed by Athyrium Capital Management”.
Websiteitem pageThe firm's website puts the investment at $25.5M.
WebsiteAthyrium Capital Managementfirm lists uMotifcompany as a current portfolio company.
WebsiteAthyrium Capital Managementfirm also worked on Corstasis Therapeuticsdeal, on Apr 2, 2026.
Websiteitem page
At a glance
Who was on each side
Parties
| Party | Role | Source |
|---|---|---|
| Athyrium Capital Management | Buyer | Websiteitem page |
Value
| Kind | Amount | Basis | Source |
|---|---|---|---|
| Investment | $25.5M | investment (stated on the firm's site) | Website |
More deals
first 2 of 6
| Date | Deal | Firms | Source |
|---|---|---|---|
| Apr 2, 2026 | Corstasis Therapeutics · Acquisition | Athyrium Capital Management | Websiteitem page |
| Apr 2, 2026 | Esperion Therapeutics · Financing | Athyrium Capital Management | Websiteitem page |
4 more deals
Deals with Athyrium Capital Management, and other deals for uMotif.
Sign up free to see the first 5, or become a member to see all 6.
On file
- Date as stated
- May 25, 2022Websiteitem page